{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T10:01:00Z","timestamp":1782554460013,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"SK Chemicals Pharmaceuticals","award":["0620213640"],"award-info":[{"award-number":["0620213640"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-04044-x","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T18:44:39Z","timestamp":1748717079000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Saliva-based lacosamide monitoring paves the way toward personalized epilepsy pharmacotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Yoonhyuk","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Jae","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Sang","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Kyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Woo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon-Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keun-Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Il","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kon","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"4044_CR1","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1212\/WNL.0000000000005756","volume":"91","author":"AM Kanner","year":"2018","unstructured":"Kanner, A. M. et al. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy. Neurology 91, 82\u201390. https:\/\/doi.org\/10.1212\/WNL.0000000000005756 (2018).","journal-title":"Neurology"},{"key":"4044_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","volume":"48","author":"E Ben-Menachem","year":"2007","unstructured":"Ben-Menachem, E. et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 48, 1308\u20131317. https:\/\/doi.org\/10.1111\/j.1528-1167.2007.01188.x (2007).","journal-title":"Epilepsia"},{"key":"4044_CR3","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","volume":"51","author":"S Chung","year":"2010","unstructured":"Chung, S. et al. Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial. Epilepsia 51, 958\u2013967. https:\/\/doi.org\/10.1111\/j.1528-1167.2009.02496.x (2010).","journal-title":"Epilepsia"},{"key":"4044_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/j.1528-1167.2012.03589.x","volume":"54","author":"G Zaccara","year":"2013","unstructured":"Zaccara, G., Perucca, P., Loiacono, G., Giovannelli, F. & Verrotti, A. The adverse event profile of lacosamide: A systematic review and meta-analysis of randomized controlled trials. Epilepsia 54, 66\u201374. https:\/\/doi.org\/10.1111\/j.1528-1167.2012.03589.x (2013).","journal-title":"Epilepsia"},{"key":"4044_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008841.pub3","author":"RK Babar","year":"2021","unstructured":"Babar, R. K., Bresnahan, R., Gillespie, C. S. & Michael, B. D. Lacosamide add-on therapy for focal epilepsy. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD008841.pub3 (2021).","journal-title":"Cochrane Database Syst. Rev."},{"key":"4044_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/ftd.0000000000000546","volume":"40","author":"PN Patsalos","year":"2018","unstructured":"Patsalos, P. N., Spencer, E. P. & Berry, D. J. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update. Ther. Drug Monit. 40, 526\u2013548. https:\/\/doi.org\/10.1097\/ftd.0000000000000546 (2018).","journal-title":"Ther. Drug Monit."},{"key":"4044_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","volume":"49","author":"PN Patsalos","year":"2008","unstructured":"Patsalos, P. N. et al. Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies. Epilepsia 49, 1239\u20131276. https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01561.x (2008).","journal-title":"Epilepsia"},{"key":"4044_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","volume":"36","author":"H Liu","year":"1999","unstructured":"Liu, H. & Delgado, M. R. Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin. Pharmacokinet. 36, 453\u2013470. https:\/\/doi.org\/10.2165\/00003088-199936060-00006 (1999).","journal-title":"Clin. Pharmacokinet."},{"key":"4044_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1528-1167.2010.02751.x","volume":"52","author":"C Greenaway","year":"2011","unstructured":"Greenaway, C., Ratnaraj, N., Sander, J. W. & Patsalos, P. N. Saliva and serum lacosamide concentrations in patients with epilepsy. Epilepsia 52, 258\u2013263. https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02751.x (2011).","journal-title":"Epilepsia"},{"key":"4044_CR10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/epi.16513","volume":"61","author":"D-Y Kim","year":"2020","unstructured":"Kim, D.-Y. et al. Usefulness of saliva for perampanel therapeutic drug monitoring. Epilepsia 61, 1120\u20131128. https:\/\/doi.org\/10.1111\/epi.16513 (2020).","journal-title":"Epilepsia"},{"key":"4044_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1365-2125.2008.03158.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan, P., Sargentini-Maier, M. L., Pigeolet, E. & Stockis, A. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br. J. Clin. Pharmacol. 66, 71\u201375. https:\/\/doi.org\/10.1111\/j.1365-2125.2008.03158.x (2008).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"4044_CR12","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1111\/epi.14023","volume":"59","author":"C Brandt","year":"2018","unstructured":"Brandt, C., Bien, C. G., Helmer, R. & May, T. W. Assessment of the correlations of lacosamide concentrations in saliva and serum in patients with epilepsy. Epilepsia 59, e34\u2013e39. https:\/\/doi.org\/10.1111\/epi.14023 (2018).","journal-title":"Epilepsia"},{"key":"4044_CR13","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1111\/epi.17399","volume":"63","author":"S-J Ahn","year":"2022","unstructured":"Ahn, S.-J. et al. Effects of CYP2C19 genetic polymorphisms on the pharmacokinetics of lacosamide in Korean patients with epilepsy. Epilepsia 63, 2958\u20132969. https:\/\/doi.org\/10.1111\/epi.17399 (2022).","journal-title":"Epilepsia"},{"key":"4044_CR14","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1093\/brain\/awac166","volume":"145","author":"WJ Lee","year":"2022","unstructured":"Lee, W. J. et al. Seronegative autoimmune encephalitis: clinical characteristics and factors associated with outcomes. Brain 145, 3509\u20133521. https:\/\/doi.org\/10.1093\/brain\/awac166 (2022).","journal-title":"Brain"},{"key":"4044_CR15","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1038\/s41598-021-85920-0","volume":"11","author":"Y Jang","year":"2021","unstructured":"Jang, Y. et al. Population pharmacokinetic model development and its relationship with adverse events of oxcarbazepine in adult patients with epilepsy. Sci. Rep. 11, 6370. https:\/\/doi.org\/10.1038\/s41598-021-85920-0 (2021).","journal-title":"Sci. Rep."},{"key":"4044_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51962","author":"S Lee","year":"2023","unstructured":"Lee, S. et al. Topiramate dosage optimization for effective antiseizure management via population pharmacokinetic modeling. Ann. Clin. Transl. Neurol. https:\/\/doi.org\/10.1002\/acn3.51962 (2023).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"4044_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000336774","volume":"89","author":"SE Kim","year":"2012","unstructured":"Kim, S. E. et al. Pharmacokinetics of lacosamide in healthy korean male volunteers. Pharmacology 89, 172\u2013178. https:\/\/doi.org\/10.1159\/000336774 (2012).","journal-title":"Pharmacology"},{"key":"4044_CR18","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaneurol.2023.2338","volume":"80","author":"P Erickson","year":"2023","unstructured":"Erickson, P. et al. Prevalence and clinical implications of a \u03b2-amyloid\u2013negative, tau-positive cerebrospinal fluid biomarker profile in alzheimer disease. Jama Neurol. 80, 969\u2013979. https:\/\/doi.org\/10.1001\/jamaneurol.2023.2338 (2023).","journal-title":"Jama Neurol."},{"key":"4044_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/FTD.0b013e31827c11e7","volume":"35","author":"PN Patsalos","year":"2013","unstructured":"Patsalos, P. N. & Berry, D. J. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther. Drug. Monit. 35, 4\u201329. https:\/\/doi.org\/10.1097\/FTD.0b013e31827c11e7 (2013).","journal-title":"Ther. Drug. Monit."},{"key":"4044_CR20","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1021\/mp300250r","volume":"9","author":"N Idkaidek","year":"2012","unstructured":"Idkaidek, N. & Arafat, T. Saliva versus plasma pharmacokinetics: Theory and application of a salivary excretion classification system. Mol. Pharm. 9, 2358\u20132363. https:\/\/doi.org\/10.1021\/mp300250r (2012).","journal-title":"Mol. Pharm."},{"key":"4044_CR21","unstructured":"(FDA), U.S. Food and Drug Adminstration VIMPAT\u00ae (lacosamide) Tablets and Injection Label, <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022253lbl.pdf> (2008)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04044-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04044-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T18:44:40Z","timestamp":1748717080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04044-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4044"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04044-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"13 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Seoul National University Hospital Institutional Review Board (IRB No. 2104-146-1213) and written informed consent was obtained from all patients and\/or legal guardians. All co-authors have reviewed and approved the contents of the manuscript, and the Scientific Reports requirements for authorship have been met. We confirm that we have read the journal\u2019s position on issues related to ethical publication and affirm that this report is consistent with those guidelines. We certify that the submission (aside from an abstract) is not under review by any other publication. No previous report overlaps with the current work. We have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"19181"}}